Asieris Pharma Doses First Patient In China Bladder Cancer Trial

March 31, 2017 -- Asieris Pharma, a China oncology pharma, has dosed the first bladder cancer patient in a pivotal Phase III trial of APL-1202, its lead candidate. Asieris aims to repurpose existing drugs while it develops novel, improved candidates for the same target. APL-1202, an oral inhibitor of MetAP2, is nitroxoline, a wide spectrum antibiotic that has been in use for 50 years and is now known to have an anti-angiogenesis effect. Asieris is headquartered in Taizhou's China Medical City and has its clinical trial office in Shanghai.